Gyre Therapeutics (GYRE)
NASDAQ:GYRE
Want to see GYRE full AI Analyst Report?
Top Page
Gyre Therapeutics
(NASDAQ:GYRE)
Select Model
Select Model
Rating:61Neutral
Price Target:
$7.50
▲(10.13% Upside)
Action:Reiterated
Date:05/15/26
The score is primarily supported by solid financial fundamentals (rapid revenue growth, very high gross margins, and low leverage) and positive corporate catalysts (Cullgen acquisition and F351 NDA priority review). This is tempered by weak technical momentum (below major moving averages, negative MACD) and valuation risk tied to current losses (negative P/E).
Positive Factors
Strong revenue growth and very high gross margins
Sustained top-line expansion with exceptionally high gross margins indicates durable unit economics and scalable products. High gross margins give pricing power and funding capacity for R&D and commercialization, supporting reinvestment and margin sustainability over the next several quarters.
Negative Factors
Profitability volatility and recent net loss
Earnings have shifted from profitable periods to a TTM loss, reflecting operating cost swings or integration expenses. Such margin volatility undermines predictability of returns, can pressure ROE, and complicates planning for sustained R&D and commercialization over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and very high gross margins
Sustained top-line expansion with exceptionally high gross margins indicates durable unit economics and scalable products. High gross margins give pricing power and funding capacity for R&D and commercialization, supporting reinvestment and margin sustainability over the next several quarters.
Read all positive factors
Gyre Therapeutics (GYRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$585.84M
Dividend YieldN/A
Average Volume (3M)102.52K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth16.30%
EPS Growth-182.23%
CountryUS
Employees579
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding96,994,000
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue4.81
Enterprise Value/Gross Profit5.06
Enterprise Value/Ebitda220.60
Forecast
1Y Price Target
$19.00Price Target Upside179.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$137.03M
Gyre Therapeutics Business Overview & Revenue Model
Company Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug appro...
How the Company Makes Money
null...
Gyre Therapeutics Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 117.05M | 116.59M | 105.76M | 113.45M | 102.29M | 7.34M |
| Gross Profit | 111.30M | 111.17M | 101.87M | 108.81M | 97.50M | -332.00K |
| EBITDA | 2.55M | 14.01M | 17.82M | 20.33M | 10.33M | -87.64M |
| Net Income | -6.29M | 5.03M | 12.09M | -92.93M | 2.30M | -87.93M |
Balance Sheet | ||||||
| Total Assets | 162.01M | 166.13M | 125.41M | 116.54M | 84.75M | 55.66M |
| Cash, Cash Equivalents and Short-Term Investments | 37.50M | 52.42M | 26.67M | 33.51M | 25.18M | 46.85M |
| Total Debt | 823.00K | 939.00K | 1.60M | 409.00K | 613.00K | 2.38M |
| Total Liabilities | 25.03M | 23.85M | 27.00M | 102.59M | 12.54M | 14.57M |
| Stockholders Equity | 101.31M | 106.03M | 63.32M | -15.83M | 42.52M | 41.09M |
Cash Flow | ||||||
| Free Cash Flow | 3.04M | -180.00K | -6.77M | 17.31M | 5.68M | -84.59M |
| Operating Cash Flow | 4.32M | 1.01M | -3.64M | 25.89M | 10.68M | -83.75M |
| Investing Cash Flow | -5.50M | -474.00K | -19.88M | -19.76M | -13.81M | 48.19M |
| Financing Cash Flow | 23.05M | 24.38M | 2.10M | 2.50M | 0.00 | 49.55M |
Gyre Therapeutics Technical Analysis
Negative
6.81
Price Trends
7.29
Negative
7.60
Negative
7.66
Negative
Market Momentum
-0.35
Positive
34.39
Neutral
5.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Negative. The current price of 6.81 is below the 20-day moving average (MA) of 7.20, below the 50-day MA of 7.29, and below the 200-day MA of 7.66, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 34.39 is Neutral, neither overbought nor oversold. The STOCH value of 5.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GYRE.
Gyre Therapeutics Risk Analysis
Gyre Therapeutics disclosed 97 risk factors in its most recent earnings report. Gyre Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gyre Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $585.84M | -18.47 | -6.27% | ― | 16.30% | -182.23% | |
58 Neutral | $1.50B | ― | -24.50% | ― | ― | -0.43% | |
56 Neutral | $1.43B | ― | -1057.44% | ― | ― | -13.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.99B | -15.04 | -42.66% | ― | ― | -33.07% |
* Healthcare Sector Average
GYRE
Gyre Therapeutics
6.18
-5.03
-44.87%
KALV
KalVista Pharmaceuticals
26.77
15.35
134.41%
TYRA
Tyra Bioscience
33.02
23.43
244.32%
MBX
MBX Biosciences, Inc.
31.79
19.28
154.12%
Gyre Therapeutics Corporate Events
Business Operations and StrategyM&A Transactions
Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion
Positive
May 14, 2026
On May 15, 2026, Gyre Therapeutics planned to present a detailed corporate and scientific update at a conference in Shanghai, highlighting its expanded pipeline and recently announced acquisition of protein degrader specialist Cullgen. The company...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Gyre Therapeutics’ F351 NDA Accepted for Priority Review
Positive
May 12, 2026
On May 12, 2026, Gyre Therapeutics announced that China’s Center for Drug Evaluation has accepted a New Drug Application for F351 (hydronidone), its lead liver fibrosis candidate, as a treatment for chronic hepatitis B-induced liver fibrosis...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition
Positive
May 4, 2026
On May 4, 2026, Gyre Therapeutics completed its previously announced all-stock, approximately $300 million acquisition of Cullgen Inc., a clinical-stage developer of targeted protein degraders and degrader-antibody conjugates, with Cullgen becomin...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Gyre Therapeutics Files NDA in China for F351
Positive
Mar 23, 2026
On March 22, 2026, Gyre Pharmaceuticals submitted a New Drug Application to China’s Center for Drug Evaluation for F351 (Hydronidone), its lead therapy for chronic hepatitis B-induced liver fibrosis. The filing marked a key regulatory milest...
Business Operations and StrategyFinancial Disclosures
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs
Positive
Mar 12, 2026
At a March 10, 2026 investor conference, Gyre Therapeutics outlined expectations that its Hydronidone (F351) liver fibrosis program could generate approximately $400 million to $600 million in revenue within five years, while its ETUARY lung fibro...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
Positive
Mar 2, 2026
On March 2, 2026, Gyre Therapeutics agreed to acquire privately held Cullgen Inc. in an all-stock deal valuing Cullgen at roughly $300 million, with Cullgen to become a wholly owned subsidiary and the merger structured as a tax-free reorganization...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.